Quadrature Capital’s Forte Biosciences FBRX Stock Holding History

Quadrature Capital’s Portfolio FBRX Stock Details FBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-18,622	Closed	-$482K	–	1738
2026 Q1	$482K	Buy	18,622 +1,049	+6%	+$30.2K	0.01%	801
2025 Q4	$479K	Buy	+17,573	New	+$308K	﹤0.01%	705

Other funds holding FBRX

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Quadrature Capital's FBRX Position: Q2 2026 in Review

Quadrature Capital sold out of Forte Biosciences (FBRX) in Q2 2026, closing a stake of 18,622 shares — an estimated $482K sold.

Quadrature Capital first reported a position in FBRX in Q4 2025 and held it in 2 quarters. The position peaked at $482K in Q1 2026. 86 funds tracked by Wall St. Rank hold FBRX as of Q2 2026.

Quadrature Capital reported no remaining Forte Biosciences position as of Q2 2026 after selling out during the quarter.
Quadrature Capital sold 18,622 Forte Biosciences shares in Q2 2026, an estimated $482K.
Quadrature Capital first reported a position in Forte Biosciences in Q4 2025 and held it in 2 quarters.
Quadrature Capital's Forte Biosciences position peaked at $482K in Q1 2026.
86 funds tracked by Wall St. Rank held Forte Biosciences as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.